01 October 2024

UPSA acquires Sérélys Pharma® and commits to women’s health

UPSA announces the completion of the acquisition of Sérélys Pharma®, a leading French company in women’s well-being. This positions UPSA in a historically underserved sector with strong growth potential.

A Rapidly Evolving Sector: Better Understanding Female Hormonal Disorders

The specific disorders related to hormonal changes that women experience throughout their lives—whether premenstrual syndrome, post-partum discomforts, or those associated with menopause—are becoming less taboo, which is good news: in France alone, 80% of women over 45 suffer to varying degrees from menopause-related symptoms (hot flashes, mood and sleep disturbances…). According to the WHO, there are over 1 billion women affected worldwide.

These women often remained without solutions due to concerns raised in the 2000s about the side effects of hormonal treatments. As a specialist in pain management and self-medication for nearly 90 years, UPSA felt compelled to address this major public health challenge for all these women.

Innovative Technology Based on Pollen: CyTonin® Technology

Sérélys Pharma® has developed a unique patented technology based on the extraction of natural active ingredients from pollen, called CyTonin®. Since Antiquity, pollen has been recognized as a superfood, a natural reservoir of many nutrients (amino acids, vitamins, fatty acids, trace elements…) beneficial for physical and mental health.

For the first time, thanks to CyTonin®, these nutrients are isolated from the rigid shell of pollen grains to become more easily absorbed by the human body.

Convincing Clinical Results and a Natural Offering

Clinical studies have demonstrated statistically significant efficacy: after two months of use, hot flashes are reduced by 50% compared to placebo in patients. The resulting treatments are 100% natural, without hormones or substances with phytoestrogenic activity, minimizing the risk of side effects. Their efficacy is scientifically proven and measured by over thirty clinical studies; it is recognized by leading scientific societies and recommended by the International Society of Gynecological Endocrinology.

“Today, women no longer want to endure the disorders related to hormonal changes throughout their lives,” says Isabelle Van Rycke, President and CEO of UPSA. “As a woman leader, the idea that I could help address such a fundamental issue as women’s health and well-being became obvious. As a specialist in family health for nearly 90 years, UPSA had to listen to this need, which has become audible thanks to societal evolution. With the acquisition of Sérélys Pharma®, UPSA is proud to stand by women by offering safe, natural, and effective solutions.”

“At this stage of our development,” explains Sossio Morra, CEO of Sérélys Pharma®, “our SME needed to partner with a laboratory better known to the general public to continue progressing. Being acquired by UPSA is a great opportunity for our exclusive technology to benefit more women while continuing to grow within a human-scale company.”

International Perspectives and Growth Plan

Present in about fifty countries, Sérélys Pharma® generates three-quarters of its sales outside France, opening new markets for UPSA in the Middle East, North and South America, and notably China.

This promising acquisition, the first for UPSA in over thirty years, fits into its growth plan and will help establish UPSA as a major international player in family health and women’s well-being.

Back to news